Hervolution has been awarded an EU grant to further explore the role of IPT001 in oncological immunotherapy approaches against hard to treat cancers
This initiative aims to advance our understanding of the potential applications of IPT001 in enhancing oncological immunotherapy, ultimately contributing to the development of more effective treatment strategies for cancer patients. “Significant progress has been made as Hervolution secures a substantial EU fund to expand its research efforts into utilizing IPT001 within the field of oncological […]
Hervolution receives 2.5M EUR in funding through the European Innovation Council Accelerator
We are beyond proud to announce that Hervolution is one of just 65 European companies to receive funding through the European Innovation Council Accelerator. Being selected among more than 4000 applicants, the funding of €2.5m
